Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10469338 | 0.69 | NOS3 (0.35) | KMT2A | |
| SCHEMBL4870613 | 0.69 | NOS3 (0.35) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL10341922 | 0.68 | ATM (0.41) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL11534822 | 0.64 | TERT (0.35) | MAOAALDH1A1KMT2A | |
| SCHEMBL10513467 | 0.63 | BCKDK (0.34) | — | |
| SCHEMBL10341772 | 0.63 | KMT2A (0.40) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL11723121 | 0.62 | HRH4 (0.44) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL11723138 | 0.62 | HRH4 (0.44) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL27431138 | 0.61 | NOS3 (0.59) | ALDH1A1KMT2A | |
| SCHEMBL11658932 | 0.59 | NOS3 (0.45) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | Neuberger, Timothy | 2008-03-20 | — | — | US | disclosed |
| US-7271187-B2 | Compositions and methods for promoting tissue regeneration | Neuberger, Tim (US) | 2007-09-18 | — | — | US | disclosed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | disclosed |
| WO-2001076592-A1 | COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION | ACORDA THERAPEUTICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | TST, DCX, GAP43 | MAOA 2786/4885CHEK1 4447/4885ALDH1A1 381/4885 |
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | GAP43, DCX, BDNF | MAOA 2786/4885CHEK1 4341/4885ALDH1A1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.